Alzheimer’s patients in the country will now have the option of receiving a new treatment, with pharmaceutical giant Eli Lilly launching donanemab in the Indian market under the brand name Lormalzi. The once-a-month 350 mg infusion has been shown to slow the progression of the disease by dissolving the amyloid beta protein plaques in the brain — a classical sign of the neuro-degenerative disease.

It is a monoclonal antibody treatment for Alzheimer’s. This is a disease-modifying therapy that uses laboratory-made proteins to target and remove amyloid-beta plaques from the brain, slowing cognitive decline in early-stage patients by roughly 30%.…